Vaccine COVISHIELD Completes Enrolment of Phase 3 Clinical Trials

The Indian Council of Medical Research (ICMR) and Serum Institute of India (SII) have announced that the enrolment of phase 3 clinical trials for potential COVISHIELD vaccine has been completed on November 12, 2020. COVISHIELD is a potential candidate of COVID-19.


The site fee for the clinical trial of the potential COVISHIELD vaccine was funded by ICMR. However, other expenses for the trial was funded by SII. Currently, ICMR and SII have been conducting phase 3 of the clinical trial of potential COVISHIELD vaccine at 15 different centres all across the country. The potential vaccine has already completed the enrolment of all 1,600 participants on October 31, 2020.


This potential vaccine for the COVID-19 has been developed at the Serum Institute of India, Pune laboratory. The vaccine is being currently tested in large efficacy trials in Brazil, UK, USA, and South Africa. The results from the clinical trials have shown that COVISHIELD can be a realistic solution for this COVID-19 pandemic. The vaccine is being claimed as the most advanced vaccine in human testing in India.

ICMR – SII Collaboration

ICMR has played a key role to strengthen the India’s fight against COVID-19 Virus. In the fight, SII has always collaborated in the clinical development. The collaboration between these two institute will further put India at the front to develop an effective vaccine. The  partnership further boost the significance of public-private institutes that are collaborating to scale up the management and containing the virus.  The SII and ICMR institutes have decided to further collaborate for the clinical development of COVOVAX, the vaccine which has been developed by US-based NOVAVAX. This vaccine has been upscaled by Serum Institute of India.